Some еpidemic indicators of increase in COVID-19 incidence in Russia in 2020–2023


DOI: https://dx.doi.org/10.18565/epidem.2024.14.4.6-12

Sizikova T.E., Karulina N.V., Saifulina N.A., Lebedev V.N., Borisevich S.V.

48 Central Scientific Research, Ministry of Defens of the Russia Federation, Sergiev Posad, Russia 
Objective. The analysis of some epidemic index of rises of COVID-19 morbidity in Russia in March 2020 – November 2023.
Materials and methods. Date from Internet resources Stopcoronavirus.rf, Yandex DataLens [Yandex DataLensс, Gogov.ru portal], and data of research, published in foreign and domestic scientist publication is used for conducting analyses.
Results. The cause of existing of rises of COVID-19 morbidity in Russia are or season’s factor (second, forth, seventh, and ninth rises) or spreading of new variants of SARS-CoV-2 virus. The genovariants of SARS-CoV-2 virus may essentially difference on epidemic characteristics of caused disease. The genovariant «Delta» is the most pathogenicity from all known variants of SARS-CoV-2 virus. the genovariant «Omicron» is the most transmissive. The maximum number of COVID-19 cases per day (203949 certificated cases) was registered during fifth rise of morbidity (dominant agent-BA.2 line of «Omicron» genovariant). The most highly index of lethality were registered during third (3,45%) and fourth (3,51%) rises of morbidity (dominant agent – the «Delta» genovariant).
Conclusion. The nine rises of morbidity were registered from the beginning of COVID-19 epidemic in Russia (March 2020). The epidemic characteristics of next rise of morbidity depend mainly on from dominant agent of SARS-CoV-2 virus and herd immunity. The main direction of natural evolution of SARS-CoV-2 virus during COVID-19 pandemic is the existing of virus genovariants with high transmissivity level, but lower pathogenicity. From beginning of 2022 the most wide spread variant of SARS-CoV-2 virus was omicron genovariant (B1.1.529) and their sublines BA.2, BA.2.75, («Centaur»), BA.5 («Czerber»), XBB.1.5 («Kraken»), XBB 1.16 («Arktur»), BA.2.86, («Pirola»). The reduction for every new rise of morbidity (began with sixth) the index of mean day number of cases in common with countermand of mass vaccination define continuous reduction of herd immunity against COVID-19 аnd this disease will be endemic in Russia.

Literature


1. Shih G., Sun L.H. Specter of possible new virus emerging from central China raises alarms across Asia. Washington Post, 8 January 2020. https://flipboard.com/@WachPost/specter-of-virusemering-from-central-china-raises-alarms-acrossa/aLVUQPrl5Qi6S4m5HlmRLg:a: 419161690-66088e4a98/ washingtonpost.com


2. Официальная статистика коронавируса. https://gogov.ru/articles/covid-19.


3. Ющук Н.Д., Мартынов Ю.В. Эпидемический процесс. В кн. Эпидемиология: Учеб. пособие. 2-е изд., перераб. и доп. М.: Медицина; 2003: 21, 23–24.


Yushchuk N.D., Martynov Y.V. [The Epidemic process. In: Epidemiology: Textbook]. 2th еd. Мoscow: Medicine; 2003: 21, 23–24. (In Russ.).


4. Гундаров И.А., Гундаров Б.И. Загадки волн респираторных вирусных инфекций. https://ibzh.ru/zagadki-voln-respiratornyh-virusnyh-infekciy-t1766/#p4272


Gundarov I.A., Gundarov B.I. [The mysteries of wave of respiratory virus infection]. (In Russ.). https://ibzh.ru/zagadki-voln-respiratornyh-virusnyh-infekciy-t1766/#p4272


5. Борисевич С. В., Сизикова Т.Е., Лебедев В. Н. Пандемия COVID-19: Анализ возможных сценариев развития эпидемии заболевания в России. Вестник войск РХБ защиты 2020; (1): 116–30. DOI:10.35825/2587-5728-2020-4-2-116-130


Borisevich S.V., Sizikova T.E., Lebedev V.N. [Pandemic of COVID-19: Analysis of possible Scenarios of the disease epidemic in Russia]. Journal of NBC Protection Corps 2020; (1): 116-30. (In Russ.). DOI: 10.35825/2587-5728-2020-4-2-116-130


6. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y. et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N. Engl. J. Med. 2020; 382(13): 1199–207. DOI: 10.1056/NEJMoa2001316


7. Riou J., Althaus C.L. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 2020; 25(4): 2000058. DOI: 10.2807/1560-7917.ES.2020.25.4.2000058


8. Wu J.T., Leung K., Bushman M., Kishore N., Niehus R., de Salazar P.M. et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat. Med. 2020; 26(4): 506–10. DOI: 10.1038/s41591-020-0822-7


9. Singanayagam A., Hakki S., Dunning J., Madon K.J., Crone М.А., Koycheva А. et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect. Dis. 2022; 22(2): 183–95. DOI: 10.1016/S1473-3099(21)00648-4.


10. Sanche S., Lin Y.T., Xu C., Romero-Severson Е., Hengartner N., Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg. Infect. Dis. 2020; 26(7): 1470–7. DOI: 10.3201/eid2607.200282.


11. Акимкин В.Г., Попова А.Ю., Хафизов К.Ф., Дубоделов Д.В., Углева С.В., Семененко Т.А. и др. COVID-19: эволюция пандемии в России. Сообщение II: динамика циркуляции геновариантов вируса SARS-CoV-2. Журнал микробиологии, эпидемиологии и иммунобиологии 2022; 99(4): 381–96. DOI: 10.36233/ 0372-9311-295


Akimkin V.G., Popova A.Y., Hafizov K.F., Dubodelov D.V., Ugleva S.V., Semenenko T.A. et al. [COVID-19: evolution of pandemic in Russia. Report 2: The dynamics of circulation of SARS-CoV-2 genovariants]. Journal of microbiology, epidemiology and immunology 2022; 99(4): 381–96. (In Russ.). DOI: 10.36233/ 0372-9311-295


12. Tracking SARS-CoV-2 variants. www.who.int


13. Covid infections rising again across UK–ONS. BBC News. 11 March 2022. https://en.org/wiki/COVID-19_pandemic_in_the_United_Kingdom


14. ECDC. Changes to list of SARS-CoV-2 variants of concern, variants of interest, and variants under monitoring. (12 May 2022). https://www.ecdc.europa.eu/sites/default/files/documents/Variants%20page%20changelog.pdf


15. SARS-CoV-2 Variant Classifications and Definitions. CDC.gov. Centers for Disease Control and Prevention. 11 February 2020. Archived from the original on 29 June 2021.


16. Russell P. Omicron XBB.1.5: What Do We Know So Far? https://www.medcape.co.uk


17. Статистика вакцинации от коронавируса в России и в мире https://gogov.ru/articles/covid-v-stats


[Statistics of vaccination against coronavirus in Russia and in the World]. (In Russ.). https://gogov.ru/articles/covid-v-stats


18. Ferguson N., Ghani A., Cori A., Hogan A., Hinsley W., Volz E. Growth, population distribution and immune escape of the Omicron in England (Technical report). WHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis. Imperial College London. DOI: 10.25561/93038.


19. Goldberg Y., Mande M.l., Bar-On Y.M., Bodenheimer O., Freedman L., Ash N., et al. Protection and waning of natural and hybrid COVID-19 immunity BMJ YALE 2021, December,4 DOI: 10.1101/2021.12.04.21267114


20. Gazit S., Shlezinger R., Perez G., Lotan R., Peretz A., Ben-Tov A. et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. medRxiv preprint DOI: 10.1101/2021.08.24.21262415; this version posted August 25, 2021


21. Акимкин В.Г., Давидова Н.Г., Углева С.В., Понежева Ж.Б., Шабалина С.В. Формирование очагов COVID-19 в закрытых коллективах. Эпидемиол. инфекц. болезни. Актуал. вопр. 2022; 12(2): 52–9. DOI: 10.18565/epidem.2022.12.2.55-9


Akimkin V.G., Davidova N.G., Ugleva S.V., Ponegeva G.B., Shabalina S.V. [The forming of COVID-19 outbreaks in closed collectives]. Epidemiоlоgy and infectious diseases. Сurrent items 2022; 12(2): 52–9. (In Russ.). DOI: 10.18565/epidem.2022.12.2.55-9


22. Cele S., Jackson L., Khoury D.S., Khan K., Moyo-Gwete T., Tegally H. et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv [Preprint]. 2021 Dec 17:2021.12.08.21267417. DOI: 10.1101/2021.12.08.21267417


About the Autors


Tatyana E. Sizikova, Cand. Biol. Sci., Leading Researcher,\48 Central Scientific Research Institute» Ministry of Defens of Russian Federation, Sergiev Posad, Russia;  48cnii@mil.ru; https://orcid.org/0000-0002-1817-0126
Natalya V. Karulina, Cand. Biol. Sci., Leading Researcher 48 Central Scientific Research Institute. e Ministry of Defens of Russian Federation, Sergiev Posad, Russia; 48cnii@mil.ru; https://orcid.org/0000-0001-7781-5249
Natalya A. Saifulina, Junior Researcher «48 Central Scientific Research Institute» of the Ministry of Defens of Russian Federation, Sergiev Posad, Russia; 48cnii@mil.ru; https://orcid.org/0009-0003-9531-9216
Professor Vitaliy N. Lebedev, BD, Junior Researcher 48 Central Scientific Research Institute Ministry of Defens of Russian Federation, Sergiev Posad, Russia; 48cnii@mil.ru; https://orcid.org/0000-0002-6552-4599
Professor Sergey V. Borisevich, Academician of Russian Academy of Sciences, BD, Head of Institute 48 Central Scientific Research Institute» Ministry of Defens of Russian Federation, Sergiev Posad, Russia; 48cnii@mil.ru; https://orcid.org/0000-0002-6742-3919


Similar Articles


Бионика Медиа